

Ref. No: 2725
Date: 30/07/26
Subject: Use of Biologics in Secondary Care

REQUEST

I would be grateful if you could respond with the number of patients treated with specific medicines between the start of April 2026 and the end of June 2026, or the latest three-month period for which data is available. Please include data for all hospitals in your organization.

Q1. How many patients were treated **in total, regardless of diagnosis**, with the following medicines in the 3 months between the start of April 2026 and end of June 2026?

Name of medicine	Number patients treated
1.1 Benralizumab (Fasenra)	
1.2 Depemokimab (Exdensur)	
1.3 Dupilumab (Dupixent)	
1.4 Mepolizumab (Nucala)	
1.5 Omalizumab (Xolair)	
1.6 Reslizumab (Cinqaero)	
1.7 Tezepelumab (Tezspire)	

Q2. How many patients were treated for **severe asthma, COPD, CRwNP** with the following medicines in the 3 months between the start of April 2026 and end of June 2026?

Name of medicine	Severe asthma (please include all types or references to asthma)	Chronic Obstructive Pulmonary Disease (COPD)	Chronic rhinosinusitis with nasal polyps (CRwNP)
2.1 Benralizumab (Fasenra)			
2.2 Depemokimab (Exdensur)			

2.3 Dupilumab (Dupixent)			
2.4 Mepolizumab (Nucala)			
2.5 Omalizumab (Xolair)			
2.6 Reslizumab (Cinqaero)			
2.7 Tezepelumab (Tezspire)			

Q3. How many patients were treated for **Atopic Dermatitis** with the following medicines in the 3 months between the start of April 2026 and end of June 2026?

Name of medicine	Number of patients with Atopic Dermatitis	Number of patients with <u>Chronic Spontaneous Urticaria (CSU)</u>
3.1 Dupilumab (Dupixent)		

Q4. How many patients were treated **by department** in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2026 and end of June 2026?

Name of medicine	Respiratory departments	Dermatology departments	Other departments
4.1 Benralizumab (Fasenra)			
4.2 Depemokimab (Exdensur)			
4.3 Dupilumab (Dupixent)			
4.4 Mepolizumab (Nucala)			
4.5 Omalizumab (Xolair)			
4.6 Reslizumab (Cinqaero)			
4.7 Tezepelumab (Tezspire)			

RESPONSE

Q1. How many patients were treated **in total, regardless of diagnosis**, with the following medicines in the 3 months between the start of April 2026 and end of June 2026?

Name of medicine	Number patients treated
1.1 Benralizumab (Fasenra)	0
1.2 Depemokimab (Exdensur)	0
1.3 Dupilumab (Dupixent)	151
1.4 Mepolizumab (Nucala)	0
1.5 Omalizumab (Xolair)	24
1.6 Reslizumab (Cinqaero)	0
1.7 Tezepelumab (Tezspire)	0

Q2 and Q3 – unable to answer as we don't hold information about indications.

Q4. How many patients were treated **by department** in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2026 and end of June 2026?

Name of medicine	Respiratory departments	Dermatology departments	Other departments
4.1 Benralizumab (Fasenra)			
4.2 Depemokimab (Exdensur)			
4.3 Dupilumab (Dupixent)		145	<5
4.4 Mepolizumab (Nucala)			
4.5 Omalizumab (Xolair)	<5	19	
4.6 Reslizumab (Cinqaero)			
4.7 Tezepelumab (Tezspire)			